See the Full Picture.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eurovision
Social Media
Soccer
Donald Trump
Formula 1
Natural Disasters
South America
Artificial Intelligence
European Union
World Cup
Manchester United
Vladimir Putin
Published • loading... • Updated

Dr Ali on the Efficacy of CDK4/6 Inhibition in ER+, HER2+ Breast Cancer

Summary by onclive.com
Azka Ali, MD, discusses how data from the PATINA trial inform the role of CDK4/6 inhibition in ER-positive, HER2-positive breast cancer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
onclive.comonclive.com

Dr Ali on the Efficacy of CDK4/6 Inhibition in ER+, HER2+ Breast Cancer

Azka Ali, MD, discusses how data from the PATINA trial inform the role of CDK4/6 inhibition in ER-positive, HER2-positive breast cancer.

Read Full Article
oncnursingnews.comoncnursingnews.com

How CDK4/6 Inhibitors Enable More Personalized Treatment in HR+ mBC

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

oncnursingnews.com broke the news in on Friday, May 16, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Breast Cancer

Breast Cancer

Maryland

Maryland

News
For You
SearchBlindspotLocal